Erkin Isakovich Musabaev
Research Subjects
Erkin Isakovich Musabaev has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Iroda Pulatovna Sharipova
Research Institute of Virology, 7a, Yangi shahar, Yunus Abad, Tashkent, 100194, Uzbekistan
2 shared publications - A. I. Grekova
Smolensk State Medical University
1 shared publication - A. U. Sabitov
Ural State Medical University
1 shared publication - Adolat Mirzaeva
Institute of Zoology of the Academy of Sciences of the Republic of Uzbekistan, Tashkent, Uzbekistan; Research Institute of Virology, Tashkent, Uzbekistan
1 shared publication - Aigul Raissova
KazNMU named after S. D. Asfendiyarov, Institute of Gastroenterology, Hepatology and Metabolism Interna Clinic LLP
1 shared publication - Aleksander V. Gorelov
Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication
Latest Publications
- Open Access
- 8 September 2026
- Published by Elsevier in Ticks and Tick-borne Diseases
- Vol. 17 (5) , 102711
Molecular screening, regional infection patterns and phylogenetic characterization of spotted fever group Rickettsia in ticks from domestic animals in Uzbekistan
- 8 September 2026
- Published by Elsevier in Ticks and Tick-borne Diseases
- Vol. 17 (5) , 102711
Open AccessMolecular screening, regional infection patterns and phylogenetic characterization of spotted fever group Rickettsia in ticks from domestic animals in Uzbekistan
- Open Access
- 16 December 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1721
Epidemiology of high-risk HPV in Uzbekistan among 44,000 women – genotypes, risk profiles and screening needs in Uzbekistan
Cervical cancer imposes a substantial public health burden in Uzbekistan, yet comprehensive HPV epidemiological data are lacking. This study characterized high-risk HPV prevalence, genotype distribution, risk factors, and screening coverage in three key regions. We analyzed data from 44,497 women aged ≥ 20 years attending gynecological services in Tashkent, Andijan, and Samarkand (2021–2023). Liquid-based cytology and HPV DNA testing for 12 high-risk genotypes were performed. Sociodemographic, reproductive, behavioral, and clinical variables were collected via standardized questionnaires and examination. Multivariable logistic regression identified associated factors of high-risk HPV infection. High-risk HPV was detected in 3,779 women (8.5%), with regional prevalence of 9.2% in Andijan, 8.8% in Tashkent, and 6.5% in Samarkand. Mixed genotype infections comprised 52.8% of cases; HPV-16/18 accounted for 41.1%. Among HPV-positive women undergoing cytology (n = 2,275), 64.1% had negative findings, 14.7% LSIL, 8.4% ASC-US, 6.9% HSIL, 5.1% ASC-H, 0.5% atypical glandular cells, and 0.3% carcinoma. Independent predictors of HPV infection included younger age, single marital status, lower parity, abortion history, and hormonal contraception (all p < 0.05). Foamy vaginal discharge was a significant clinical predictor (adjusted OR 1.53; p < 0.01). Uzbekistan exhibits an intermediate high-risk HPV burden, dominated by vaccine-preventable genotypes, and low screening coverage. Targeted outreach to identified high-risk groups—by age, reproductive history, and clinical features—will optimize resource allocation. These data support accelerated progress toward WHO elimination targets in Uzbekistan. The online version contains supplementary material available at 10.1186/s12879-025-12096-7.
- 16 December 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1721
Open AccessEpidemiology of high-risk HPV in Uzbekistan among 44,000 women – genotypes, risk profiles and screening needs in Uzbekistan
Cervical cancer imposes a substantial public health burden in Uzbekistan, yet comprehensive HPV epidemiological data are lacking. This study characterized high-risk HPV prevalence, genotype distribution, risk factors, and screening coverage in three key regions. We analyzed data from 44,497 women aged ≥ 20 years attending gynecological services in Tashkent, Andijan, and Samarkand (2021–2023). Liquid-based cytology and HPV DNA testing for 12 high-risk genotypes were performed. Sociodemographic, reproductive, behavioral, and clinical variables were collected via standardized questionnaires and examination. Multivariable logistic regression identified associated factors of high-risk HPV infection. High-risk HPV was detected in 3,779 women (8.5%), with regional prevalence of 9.2% in Andijan, 8.8% in Tashkent, and 6.5% in Samarkand. Mixed genotype infections comprised 52.8% of cases; HPV-16/18 accounted for 41.1%. Among HPV-positive women undergoing cytology (n = 2,275), 64.1% had negative findings, 14.7% LSIL, 8.4% ASC-US, 6.9% HSIL, 5.1% ASC-H, 0.5% atypical glandular cells, and 0.3% carcinoma. Independent predictors of HPV infection included younger age, single marital status, lower parity, abortion history, and hormonal contraception (all p < 0.05). Foamy vaginal discharge was a significant clinical predictor (adjusted OR 1.53; p < 0.01). Uzbekistan exhibits an intermediate high-risk HPV burden, dominated by vaccine-preventable genotypes, and low screening coverage. Targeted outreach to identified high-risk groups—by age, reproductive history, and clinical features—will optimize resource allocation. These data support accelerated progress toward WHO elimination targets in Uzbekistan. The online version contains supplementary material available at 10.1186/s12879-025-12096-7.
- Open Access
- 24 September 2025
- Published by Professional Event, LLC in Family medicine. European practices
- No. 3,p. 21-26
Expert Consensus on Improving Clinical Approaches to Managing Liver Diseases in Patients with Comorbidities
Non-alcoholic fatty liver disease affects up to 38% of the adult population worldwide, making it the most common chronic liver disease. It is a multisystem pathology, which is caused by systemic insulin resistance and related metabolic dysfunction, and lead to steatosis, steatohepatitis, fibrosis, cirrhosis and hepatocellular carcinoma, as well as to extrahepatic complications such as cardiovascular diseases, type 2 diabetes mellitus and chronic kidney disease. In 2023 the main international liver study associations have proposed to replace the term “non-alcoholic fatty liver disease” with “metabolic associated fatty liver disease” (MAFLD) to better reflect the metabolic origin of the disease. This change in terminology sparked greater scientific interest and a reassessment of clinical strategies. In March 2024, an Expert Forum on “Clinical Improvement of Approaches to Treating Liver Diseases in Comorbid Patients” brought together 16 key expert specialists of different specialities from Ukraine, Kazakhstan, Uzbekistan, Kyrgyzstan, Georgia, and Armenia. The forum focused on optimizing the treatment of MAFLD in patients with comorbid diseases. The consensus was adopted on the main recommendations: early diagnosis using modern imaging methods; lifestyle modification (diet and physical activity); pharmacotherapy; in some cases, bariatric surgery. Special attention was paid to the treatment of comorbidities, hepatogenic fatigue with ademetionine and the use of the Charlson index for survival prognosis. The document emphasizes the importance of a multidisciplinary approach, the need for further studies of pathogenesis and the development of targeted therapy. Implementation of these recommendations may improve the quality of life and long-term outcomes for patients with chronic liver disease. Conclusions. MAFLD is characterized by the accumulation of fat in the liver due to metabolic disorders. It is a common disease worldwide. Early diagnosis of the disease is vital because it can progress to severe and terminal conditions (steatohepatitis, cirrhosis, and liver cancer). Therapeutic strategies include: lifestyle changes, pharmacotherapy, and bariatric surgery. Further studies are needed to improve the understanding of the pathogenesis of MAFLD, identify biomarkers of this disease, and develop new therapeutic strategies.
- 24 September 2025
- Published by Professional Event, LLC in Family medicine. European practices
- No. 3,p. 21-26
Open AccessExpert Consensus on Improving Clinical Approaches to Managing Liver Diseases in Patients with Comorbidities
Non-alcoholic fatty liver disease affects up to 38% of the adult population worldwide, making it the most common chronic liver disease. It is a multisystem pathology, which is caused by systemic insulin resistance and related metabolic dysfunction, and lead to steatosis, steatohepatitis, fibrosis, cirrhosis and hepatocellular carcinoma, as well as to extrahepatic complications such as cardiovascular diseases, type 2 diabetes mellitus and chronic kidney disease. In 2023 the main international liver study associations have proposed to replace the term “non-alcoholic fatty liver disease” with “metabolic associated fatty liver disease” (MAFLD) to better reflect the metabolic origin of the disease. This change in terminology sparked greater scientific interest and a reassessment of clinical strategies. In March 2024, an Expert Forum on “Clinical Improvement of Approaches to Treating Liver Diseases in Comorbid Patients” brought together 16 key expert specialists of different specialities from Ukraine, Kazakhstan, Uzbekistan, Kyrgyzstan, Georgia, and Armenia. The forum focused on optimizing the treatment of MAFLD in patients with comorbid diseases. The consensus was adopted on the main recommendations: early diagnosis using modern imaging methods; lifestyle modification (diet and physical activity); pharmacotherapy; in some cases, bariatric surgery. Special attention was paid to the treatment of comorbidities, hepatogenic fatigue with ademetionine and the use of the Charlson index for survival prognosis. The document emphasizes the importance of a multidisciplinary approach, the need for further studies of pathogenesis and the development of targeted therapy. Implementation of these recommendations may improve the quality of life and long-term outcomes for patients with chronic liver disease. Conclusions. MAFLD is characterized by the accumulation of fat in the liver due to metabolic disorders. It is a common disease worldwide. Early diagnosis of the disease is vital because it can progress to severe and terminal conditions (steatohepatitis, cirrhosis, and liver cancer). Therapeutic strategies include: lifestyle changes, pharmacotherapy, and bariatric surgery. Further studies are needed to improve the understanding of the pathogenesis of MAFLD, identify biomarkers of this disease, and develop new therapeutic strategies.
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (1) , e7
Prevalence of high-risk human papillomavirus genotypes among women in Uzbekistan, 2021–2023
Sharipova IP, et al. J Gynecol Oncol. 2024 Jun;36:e7. https://doi.org/10.3802/jgo.2025.36.e7
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (1) , e7
Open AccessPrevalence of high-risk human papillomavirus genotypes among women in Uzbekistan, 2021–2023
Sharipova IP, et al. J Gynecol Oncol. 2024 Jun;36:e7. https://doi.org/10.3802/jgo.2025.36.e7